Evaluation of Inflammasome Gene Polymorphisms in Periodontitis Patients

NCT ID: NCT06465095

Last Updated: 2024-08-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

240 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-07-01

Study Completion Date

2025-04-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present study aimed to evaluate the distribution of NLRP3, AIM2, and IFI16 inflammasome gene polymorphisms in individuals with Stage III Grade B and C periodontitis and periodontally healthy individuals. 80 periodontally healthy, 80 Stage III Grade B and 80 Stage III Grade C periodontitis patients will be enrolled. Blood samples will be collected from each participants and clinical parameteres will be recorded for whole mouth. DNA isolation will be performed from all samples. The SNP regions with the numbers rs4612666, rs75985579, and rs2793845 will be detected from DNA material using Real-Time PCR device genotyping kits. Data will be analyzed using statistical tests.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Innate immune response is the first line of defense mechanism of the body against pathogens. One of the most important proteins involved in the innate immune response are the inflammasomes which are multimeric protein complexes composed of a sensor molecule (the PRR), typically the adapter molecule apoptosis-associated speck-like protein containing a caspase-recruitment domain (CARD), and the protease caspase-1. Different types of inflammasomes have been described. In periodontal disease, inflammasome activation is associated with the release of pro-inflammatory cytokines, which can lead to tissue destruction and periodontal damage.

Progression rate, onset age, and severity of periodontal disease are influenced by some modifiable or non-modifiable risk factors present in the host. Genetic polymorphisms are non-modifiable risk factors for periodontitis. Variations in inflammasome genes may be determinants in the development of periodontal disease by leading to diversity in inflammatory markers.

Sample size is determined based on a previous study which analyzes the effect of NLRP3 gene polymorphism on periodontitis susceptibility. For rs4612666 group, with an α value of 0.05 and a power of 80%, it is determined that there should be 80 participants in each group. Totally 240 patients are included (80 periodontally healthy, 80 Stage III Grade B periodontitis, 80 Stage III Grade C periodontitis). The whole mouth clinical periodontal examination includes measurement of probing depth (PPD), clinical attachment level (CAL), presence of bleeding on probing (BOP), gingival index (GI), and plaque index (PI) at 6 sites per tooth, except the third molars. Periodontal diagnosis of each patient has been made according to the 2017 World Workshop on Classification of Periodontal and Peri-Implant Diseases and Conditions. Healthy group includes individuals without a clinical inflammation pattern and a history of periodontitis, with no detected clinical attachment and bone loss, BOP \< 10%, probing depth ≤ 3 mm. Stage III Grade B periodontitis patients have minimum of 20 teeth (except third molars), with CAL ≥ 5 mm, probing depth ≥ 6mm, and radiographically showing bone loss extending up to one-third of the root, percantage of bone lose by age is 0.25-1 and Stage III Grade C patients have minimum of 20 teeth (except third molars), with CAL ≥ 5 mm, probing depth ≥ 6mm, and radiographically showing bone loss extending up to one-third of the root, percantage of bone lose by age is \>1.

Sample Collection and DNA Isolation and Genotyping A total of 5 mL of blood is collected from the antecubital fossa by venepuncture method from each participants and stored at -80°C until analysis day. DNA isolation has been made using genomic DNA kits. rs4612666, rs75985579, and rs2793845 SNP regions are detected from DNA material using Real-Time PCR device genotyping kits.

Statistical analysis has been performed with standard statistical software package by selecting appropriate tests.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Periodontal Diseases Periodontitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy

Individuals without a clinical inflammation pattern and a history of periodontitis, with no detected clinical attachment and bone loss, BOP \< 10%, probing depth ≤ 3 mm.

Baseline

Intervention Type GENETIC

Measurements and sampling

Stage III Grade B Periodontitis

Individuals that have minimum of 20 teeth (except third molars), with CAL ≥ 5 mm, probing depth ≥ 6mm, and radiographically showing bone loss extending up to one-third of the root, percantage of bone lose by age is 0.25-1 will be included.

Baseline

Intervention Type GENETIC

Measurements and sampling

Stage III Grade C Periodontitis

Individuals that have minimum of 20 teeth (except third molars), with CAL ≥ 5 mm, probing depth ≥ 6mm, and radiographically showing bone loss extending up to one-third of the root, percantage of bone lose by age is \>1 will be included.

Baseline

Intervention Type GENETIC

Measurements and sampling

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Baseline

Measurements and sampling

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* systematically healthy, non-smoker individuals
* patients between the ages of 18 and 65
* individuals with periodontally healthy, stage III grade B and C periodontitis diagnoses

Exclusion Criteria

* having any diagnosed medical disorders such as diabetes mellitus, cardiovascular diseases, rheumatoid arthritis...
* Usage of antibiotics, non-steroidal anti-inflammatory drugs and immunosuppressive agents within the past 6 months.
* Periodontal treatment within the preceding 6 months.
* Pregnant/ lactating/ postmenopausal females.
* Current orthodontic treatment.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Marmara University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Marmara University

Istanbul, Maltepe, Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hafize Öztürk Özener

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

09-2023-1700

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

I-Smads in Periodontitis
NCT04846166 COMPLETED
miRNAs in Periodontal Disease
NCT05046678 COMPLETED